natgillin/translations-raw huggingface dataset:
In particular, you should not be given MabCampath within 3 weeks of taking any other anti-cancer 
Zlasti pomembno je, da zdravila MabCampath ne dobite manj kot 3 tedne pred oz. po drugih zdravilih proti raku.
The use of latex gloves and safety glasses is recommended to avoid exposure in case of breakage of the ampoule or other accidental spillage. 
Priporočljivo je uporabljati lateksne rokavice in zaščitna očala, da se prepreči izpostavljenost v primeru razbitja ampule ali drugega naključnega razlitja.
Patients should be premedicated with oral or intravenous steroids, an appropriate antihistamine and analgesic 30-60 minutes prior to each MabCampath infusion during dose escalation and as clinically indicated thereafter (see section 4.4). 
Premedikacijo s peroralnimi ali intravenskimi steroidi, primernim antihistaminikom in analgetikom je treba izvesti 30 - 60 minut pred vsakim infundiranjem zdravila MabCampath med stopnjevanjem in kot je klinično indicirano v nadaljevanju (glejte poglavje 4.4).
More than 80% of previously treated patients may be expected to experience adverse reactions; the most commonly reported reactions usually occur during 
Pri več kot 80 odstotkih predhodno zdravljenih bolnikov so bili neželeni učinki pričakovani; najpogosteje so se neželeni učinki pojavili v prvem tednu zdravljenja.
The required amount of the ampoule contents should be added, via a sterile, low-protein binding, non-fibre 5 μm filter, to 100 ml of sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose (5%) solution for infusion. 
Potrebno količino vsebine ampule je treba dodati prek sterilnega, nevlaknastega 5 μm filtra, ki malo veže beljakovine v 100 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za infundiranje ali 5 % raztopine glukoze za infundiranje.
MabCampath was administered as a 2 hour intravenous infusion, at the recommended dosing schedule, starting at 3 mg and increasing to 30 mg, 3 times weekly, for up to 12 weeks. 
Zdravilo MabCampath so intravensko infundirali 2 uri po priporočeni odmerni shemi, tako da so začeli s 3 mg odmerkom in ga povečevali do 30 mg, trikrat na teden, do 12 tednov.
MabCampath may be reinstituted after the infection or toxicity has resolved. 
Zdravljenje z zdravilom MabCampath se lahko ponovno začne, ko okužba ali toksični učinki minejo.
MabCampath is not recommended in children below 17 years of age or in patients who have kidney or 
Uporaba zdravila MabCampath ni priporočljiva pri otrocih mlajših od 17 let in pri bolnikih z boleznimi ledvic ali jeter.
Patients should be monitored carefully (see 
Bolnike je treba natančno nadzorovati (glejte poglavje 4.4).
No other findings, in the above toxicity studies, provide information of significant relevance to clinical 
Omenjene študije toksičnosti niso pokazale drugih za klinično uporabo pomembnih informacij.
No short or long term animal studies have been conducted with MabCampath to assess carcinogenic 
Kratkotrajnih ali dolgotrajnih študij zdravila MabCampath pri živalih za oceno kancerogenega in mutagenega potenciala niso izvedli.
You should 
O tem vam bo
Significant Fab binding was also observed in the male reproductive tract (epididymis, sperm, seminal 
Pomembno Fab vezavo so opažali tudi v moškem reproduktivnem sistemu (epididimisu, semenčicah, semenskih vrečkah) in koži.
Medicinal products for the treatment of hypersensitivity reactions, as well as preparedness to institute emergency measures in the event of reaction during administration is necessary (see section 4.2). 
Za primer reakcij med uporabo zdravila morajo biti na razpolago zdravila za zdravljenje preobčutljivostnih reakcij kot tudi pripravljenost za izvajanje nujnih ukrepov (glejte poglavje 4.2).
In patients receiving MabCampath as first line therapy, the recovery of CD4+ counts to ≥200 cells/µl occurred by 6 months post-treatment, however, at 2 months post-treatment the median was 183 cells/l. 
Pri bolnikih, ki dobivajo zdravilo MabCampath kot zdravilo prvega izbora, se je število celic CD4+ vrnilo na število 200 celic/µl v 6 mesecih po končanem zdravljenju, v 2 mesecih po zdravljenju pa se je povprečno število celic dvignilo na 183 celic/µl.
Systemic clearance decreased with repeated administration due to decreased receptor-mediated clearance (i.e. loss of CD52 receptors in the periphery). 
Sistemski očistek se je z večkratno uporabo zmanjševal zaradi zmanjšanja receptorsko posredovanega očistka (t.j.
In the event that acute infusion reactions persist, the infusion time may be extended up to 8 hours from the time of reconstitution of MabCampath in solution for infusion. 
Če akutna reakcija zaradi infundiranja ne izzveni, je možno čas infundiranja podaljšati do 8 ur od priprave raztopine zdravila MabCampath.
Store in the original packaging in order to protect from light. 
Shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
Caution should be exercised in the handling and preparation of the MabCampath solution. 
Med pripravo in ravnanjem z raztopino MabCampath je potrebna previdnost.
MabCampath is used to treat patients with chronic lymphocytic leukaemia (CLL), a cancer of the lymphocytes (a type of white blood cell). 
Zdravilo MabCampath se uporablja za zdravljenje bolnikov s kronično limfocitno levkemijo (KLL), kar je rak limfocitov (vrsta belih krvnih celic).
If treatment is needed, breast-feeding should be discontinued during treatment and for at least 4 weeks following MabCampath therapy. 
Če je zdravljenje potrebno, je treba med zdravljenjem z zdravilom MabCampath in vsaj še 4 tedne po njem dojenje prekiniti.
Premedications 
Premedikacija
Preclinical evaluation of alemtuzumab in animals has been limited to the cynomolgus monkey because of the lack of expression of the CD52 antigen on non-primate species. 
Predklinično ocenjevanje alemtuzumaba pri živalih je bilo zaradi odsotnosti ekspresije antigena CD52 pri neprimatnih vrstah omejeno le na opice cynomolgus.
Median Age (Years) 
Mediana starosti (leta)
The active substance in MabCampath, alemtuzumab, is a monoclonal antibody. 
Zdravilna učinkovina zdravila MabCampath, alemtuzumab, je monoklonsko protitelo.
Summary of first-line patient population and outcomes Independent review of response rate and duration MabCampath n=149 
Pregled populacije in rezultatov predhodno ne zdravljenih bolnikov Neodvisen pregled stopnje odzivnosti in trajanje MabCampath n=149 Klorambucil n=148 Vrednost P
In the event of serious infection or severe haematological toxicity MabCampath should be interrupted until the event resolves. 
V primeru resne okužbe ali hudih hematoloških toksičnih učinkov je treba zdravilo MabCampath prekiniti, dokler zaplet ne mine.
53.4% Not Applicable N=82 
53,4 % ni veljavno
However, if acute moderate to severe adverse reactions such as hypotension, rigors, fever, shortness of breath, chills, rashes and bronchospasm (some of which may be due to cytokine release) occur at either the 3 mg or 10 mg dose levels, then those doses should be repeated daily until they are well tolerated before further dose escalation is attempted (see section 4.4). 
Če pa se pri 3- ali 10- mg odmerkih pojavijo akutni zmerni do hudi neželeni učinki, kot so hipotenzija, okorelost, zvišana telesna temperatura, težko dihanje, mrzlica, izpuščaji ali bronhospazem (nekateri od njih nastanejo lahko zaradi sproščanja citokinov), je treba odmerek ponavljati vsak dan, dokler ga bolnik ne prenaša dobro; šele potem pride v poštev nadaljnje povečanje odmerka (glejte poglavje 4.4).
The MAH will continue to submit yearly PSURs, unless otherwise specified by the CHMP. 
Imetnik dovoljenja za promet z zdravilom bo predložil vsakoletna Periodična poročila o varnosti (PSUR), razen če bo CHMP določil drugače.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Imetnik dovoljenja za promet:
You should stop breast-feeding when you start your treatment and you should not begin breast-feeding again until at least 4 weeks after you have finished your treatment and you have consulted your doctor 
Ne začnite znova dojiti prej kot 4 tedne po koncu zdravljenja; pred tem se morate posvetovati s svojim zdravnikom.
Transient grade 3 or 4 thrombocytopenia occurs very commonly during the first 2 weeks of therapy and then begins to improve in most patients. 
V prvih dveh tednih zdravljenja se zelo pogosto pojavi prehodna trombocitopenija 3. ali 4. stopnje, ki se pri večini bolnikov kasneje izboljša.
Because of the potential for Transfusion Associated Graft Versus Host Disease (TAGVHD) it is recommended that patients who have been treated with MabCampath receive irradiated blood 
Zaradi možnosti pojava s transfuzijo povezane bolezni presadka proti gostitelju, je priporočljivo da bolniki, ki so bili zdravljeni z zdravilom MabCampath dobijo obsevane krvne izdelke.
Data available from three uncontrolled B-CLL studies are summarised in the following table: 
Naslednja preglednica povzema podatke treh nekontroliranih študij B-KLL.
ORR was superior in patients with any 11q deletion (87% v 29%; p<0.0001) or sole deletion 13q (91% v 62%; p=0.0087) treated with MabCampath compared to chlorambucil. 
Celokupni odziv na zdravljenje je višji pri bolnikih s katerimkoli izbrisom 11q (87 % proti 29 %; p<0,0001) in izključno izbrisom 13q (91 % proti 62 %; p=0,0087), zdravljenih z zdravilom MabCampath v primerjavi z bolniki, zdravljenimi z zdravilom klorambucil.
No studies of the effects of MabCampath on the ability to drive and use machines have been performed. 
Študij o vplivu zdravila MabCampath na sposobnost vožnje in upravljanja s stroji niso izvedli.
The doctor will carefully monitor you and decide what are the appropriate amounts of MabCampath to give you during your whole treatment period. 
Zdravnik vas bo ves čas zdravljenja natančno nadzoroval in določil za vas primeren odmerek zdravila MabCampath.
In the randomized controlled trial in first line patients (Study 4), patients in the MabCampath arm were tested weekly for CMV using a PCR (polymerase chain reaction) assay from initiation through completion of therapy, and every 2 weeks for the first 2 months following therapy. 
V randomiziranem, nadzorovanem kliničnem preskušanju predhodno nezdravljenih (zdravljenje prvega izbora) bolnikov (študija 4) so pri bolnikih, zdravljenimi z zdravilom MabCampath, za ugotavljanje CMV vsak teden uporabljali PCR od začetka do konca zdravljenja ter vsaka dva tedna v prvih dveh mesecih po zdravljenju.
Other medicinal products should not be added to the MabCampath infusion solution or simultaneously infused through the same intravenous line (see section 4.5). 
Raztopini zdravila MabCampath za infundiranje se ne sme dodati drugih zdravil; prav tako se drugih zdravil ne sme hkrati infundirati po isti intravenski liniji (glejte poglavje 4.5).
During the first week of treatment, MabCampath should be administered in escalating doses: 3 mg on day 1, 10 mg on day 2 and 30 mg on day 3 assuming that each dose is well tolerated. 
Prvi teden zdravljenja je treba odmerke zdravila MabCampath postopoma povečevati: 1. dan 3 mg, 2. dan 10 mg in 3. dan 30 mg, pod pogojem, da bolnik vsak odmerek dobro prenaša.
Transient grade 3 or 4 neutropenia occurs very commonly by weeks 5-8 following initiation of treatment. 
V obdobju od 5 - 8 tednov po začetku zdravljenja se zelo pogosto pojavi prehodna nevtropenija 3. ali 4. stopnje.
Lymphocytopenia was the most common treatment-related effect in this species. 
Najpogostejši z zdravljenjem povezan učinek je bila pri tej vrsti opic limfocitopenija.
Acute adverse reactions, which may occur during initial dose escalation and some of which may be due to the release of cytokines, include hypotension, chills/rigors, fever, shortness of breath and rashes. 
Med akutnimi neželenimi učinki, ki se lahko pojavijo med začetnim stopnjevanjem odmerka (nekateri od njih se pojavijo zaradi sproščanja citokinov), so hipotenzija, mrzlica/okorelost, zvišana telesna temperatura, težko dihanje in izpuščaji.
The safety and efficacy of MabCampath were evaluated in a Phase 3, open-label, randomized comparative trial of first line (previously untreated) Rai stage I-IV B-CLL patients requiring therapy (Study 4). 
Ocena varnosti in učinkovitosti zdravila MabCampath je bila narejena pri randomiziranih predhodno nezdravljenih bolnikih s stadijem bolezni po Raiju I-IV B-KLL v 3. fazi, ki potrebujejo zdravljenje (4. študija).
You may experience an allergic or hypersensitivity reaction to MabCampath solution, especially against the protein contained in it, while the infusion is given to you. 
Pri infundiranju se lahko pojavi alergična ali preobčutljivostna reakcija na raztopino MabCampath in še posebej na beljakovino, ki jo vsebuje.
• bleeding and inflammation of the gums, blisters on the tongue, nosebleeds 
• krvavitev iz dlesni in vnetje dlesni, mehurčki na jeziku, krvavitev iz nosu
CD4 and CD8 T-cell counts begin to rise from weeks 8-12 during treatment and continue to recover for several months following the discontinuation of treatment. 
Število celic T CD4 in CD8 začne med zdravljenjem naraščati od 8.
• fever, shivering/chills, sweating, nausea (feeling sick), vomiting, low blood pressure, low white/red blood cell levels, infections including pneumonia and blood poisoning, irritation and/or blistering of the mouth region, low blood platelet levels, tiredness, rash, itching, red raised lesions on the skin, shortness of breath, headache, diarrhoea and loss of appetite. 
• zvišana telesna temperatura, drgetanje/mrzlica, znojenje, navzea (občutek slabosti), bruhanje, nizek krvni tlak, nizka raven belih/rdečih krvnih celic, okužbe (tudi pljučnica in zastrupitev krvi), draženje in/ali mehurčki v ustih, majhno število trombocitov, utrujenost, izpuščaj, srbenje, rdečkaste vzbrsti nad ravnjo kože, težko dihanje, glavobol, driska in izguba apetita.
Complete blood counts and platelet counts should be obtained at regular intervals during MabCampath therapy and more frequently in patients who develop cytopenias. 
Med zdravljenjem z zdravilom MabCampath je treba v rednih presledkih določati celotno krvno sliko in število trombocitov; določanje mora biti pogostejše pri bolnikih, pri katerih se pojavijo citopenije.
If a severe haematological toxicity develops, MabCampath treatment should be interrupted until the event resolves. 
Če se pojavi huda hematološka toksičnost, je treba zdravljenje z zdravilom MabCampath prekiniti, dokler zaplet ne mine.
If particulate matter is present or the concentrate is coloured, then the vial should not be used. 
Če so prisotni delci ali je koncentrat obarvan, se viale ne sme uporabiti.
A trend toward improved ORR was observed in patients with 17p deletion treated with MabCampath (64% v 20%; p=0.0805). 
Trend povečevanja ORR je mogoče opaziti pri bolnikih z izbrisom 17p, zdravljenih z zdravilom MabCampath (64 % proti 20 %; p=0,0805).
≥ 50% decrease from baseline in patients initiating therapy with a baseline ANC ≤ 250/μl and/or a 
≥ 50 % zmanjšanje od začetne vrednosti pri bolnikih z začetnim zdravljenjem, pri katerih je bila na začetku vrednost ANC ≤ 250/μl in/ali število trombocitov ≤ 25,000/μl
Dose modification* ANC < 250/μl and/or platelet count ≤25,000/μl 
ANC < 250/μl in/ali število trombocitov ≤ 25,000/μl
No studies have been conducted which specifically address the effect of age on MabCampath disposition and toxicity. 
Študij, ki bi specifično proučile vpliv starosti na odstranjevanje in toksičnost zdravila MabCampath, niso izvedli.
After the last 30 mg dose, the median volume of distribution at steady-state was 0.15 l/kg (range: 0.1-0.4 l/kg), indicating that distribution was primarily to the extracellular fluid and plasma compartments. 
Po zadnjem 30-mg odmerku je bila mediana volumna porazdelitve v stanju dinamičnega ravnovesja 0,15 l/kg (razpon od 0,1 do 0,4 l/kg).
MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom fludarabine combination chemotherapy is not appropriate. 
Zdravilo MabCampath je indicirano za zdravljenje bolnikov z B-celično kronično limfocitno levkemijo (B-KLL), za katere kemoterapija s fludarabinom ni primerna.
A slight cumulative effect on the degree of lymphocyte depletion was seen in repeated dose studies compared to single dose studies. 
V študijah ponavljajočih odmerkov so v primerjavi s študijami posameznih odmerkov opažali rahel kumulativen učinek na izrazitost izčrpanja limfocitov.
MabCampath pharmacokinetics followed a 2-compartment model and displayed non-linear elimination kinetics. 
Farmakokinetika zdravila MabCampath je ustrezala dvoprostorskemu modelu; kinetika izločanja ni bila linearna.
The potential for an increased risk of infection-related complications may exist following treatment with multiple chemotherapeutic or biological agents. 
Po zdravljenju z več kemoterapevtiki ali biološkimi zdravili obstaja možnost povečanega tveganja za zaplete, povezane z okužbami.
Lymphoma - like disorder 
limfomu podobna bolezen
Males and females of childbearing potential should use effective contraceptive measures during treatment and for 6 months following MabCampath therapy (see sections 4.6 and 5.3). 
Moški in ženske v rodni dobi morajo med zdravljenjem z zdravilom MabCampath in še 6 mesecev po njem uporabljati učinkovito kontracepcijo (glejte poglavji 4.6 in 5.3).
Within each frequency grouping, undesirable effects observed during treatment or within 30 days following the completion of treatment with MabCampath are presented in order of decreasing 
Neželeni učinki se lahko pojavijo v vsaki skupini (glede na pogostnost) med zdravljenjem ali v 30 dneh po končanem zdravljenju z zdravilom MabCampath.
Metabolism and nutritional disorders: Tumour lysis syndrome with fatal outcome has been reported. 
Presnovne in prehranske motnje: poročali so o sindromu razpada tumorja s smrtnim izidom.
Pregnancy MabCampath must not be administered to patients who are pregnant, therefore if you: 
Nosečnice ne smejo dobivati zdravila MabCampath, zato morate
Complete remissions were also superior in patients with sole 13q deletion treated with MabCampath (27% v 0%; p=0.0009). 
Popolna opustitev je bila prav tako boljša pri bolnikih, zdravljenih z zdravilom MabCampath, z izključnim izbrisom 13q (27 % proti 0 %; p=0,0009).
Males and females of childbearing capacity should use effective contraceptive measures during treatment and for 6 months following MabCampath therapy (see section 5.3). 
Moški in ženske v rodni dobi morajo med zdravljenjem z zdravilom MabCampath in še 6 mesecev po njem uporabljati učinkovito kontracepcijo (glejte poglavje 5.3).
• weight loss, dehydration, thirst, swelling of the lower legs, temperature change sensation, low 
• hujšanje, dehidracija, žeja, otekanje spodnjih okončin, motnje v zaznavanju temperature, nizke
It is highly recommended that anti-infective prophylaxis (e.g. trimethoprim/sulfamethoxazole 1 tablet twice daily, 3 times weekly, or other prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and an effective oral anti-herpes agent, such as famciclovir, 250 mg twice daily) should be initiated while on therapy and for a minimum of 2 months following completion of treatment with MabCampath or until the CD4+ count has recovered to 200 cells/l or greater, whichever is the later. 
Med zdravljenjem je nadvse priporočljivo uvesti protimikrobno zaščito (npr. trimetoprim/sulfametoksazol 1 tableto dvakrat na dan, trikrat na teden, ali drugo zaščito proti pljučnici zaradi Pneumocystis jiroveci (PCP) ter učinkovito peroralno sredstvo proti herpesu, npr. 250 mg famciklovirja dvakrat na dan).
Alemtuzumab is a genetically engineered humanised IgG1 kappa monoclonal antibody specific for a 21-28 kD lymphocyte cell surface glycoprotein (CD52) expressed primarily on the surface of normal and malignant peripheral blood B and T cell lymphocytes. 
Alemtuzumab je z genskim inženirstvom pridobljeno humanizirano monoklonsko protitelo IgG1 kapa, specifično za 21-28 kD površinski glikoprotein limfocitov (CD52), izražen predvsem na površini normalnih in malignih limfocitov B in T v periferni krvi.
Median PFS was superior in patients with sole 13q deletion treated with MabCampath (24.4 v 13.0 months; p=0.0170 stratified by Rai Stage). 
Srednja vrednost PFS pri bolnikih z izključnim izbrisom 13q je bila boljša, če so bili bolniki zdravljeni z zdravilom MabCampath (24,4 proti 13,0 mesecev; p=0,0170, razvrščeno glede na stadije po Raiju).
Infusion reactions: Serious and sometimes fatal reactions, including bronchospasm, hypoxia, syncope, pulmonary infiltrates, acute respiratory distress syndrome (ARDS), respiratory arrest, myocardial infarction, arrhythmias, acute cardiac insufficiency and cardiac arrest have been observed. 
Infuzijske reakcije: Poročali so o resnih in včasih usodnih reakcijah, vključno z bronhospazmom, hipoksijo, sinkopo, pljučnimi infiltrati, akutnim sindromom dihalne stiske (ARDS), zastojem dihanja, miokardnim infarktom, aritmijami, akutnim srčnim popuščanjem in zastojem srca.
Serious side effects, including difficulty in breathing, inflammation of the lungs, extreme shortness of breath, fainting, heart attack, low red blood cell and low blood platelet levels, infections, bleeding in the brain (intracranial haemorrhage) have occurred with fatal outcome. 
Pojavili so se resni neželeni učinki, vključno s težkim dihanjem, vnetjem pljuč, izredno kratko sapo, omedlevico, srčnim napadom, zmanjšanjem števila rdečih krvnih celic in zmanjšanjem števila trombocitov v krvi, okužbami, krvavitvijo v možganih (intrakranialna krvavitev), ki so bili usodni.
Alemtuzumab is a genetically engineered humanised IgG1 kappa monoclonal antibody specific for a 21-28 kD lymphocyte cell surface glycoprotein (CD52). 
Alemtuzumab je z genskim inženirstvom pridobljeno humaniziranoo monoklonsko protitelo IgG1 kapa, specifično za 21-28 kD površinski glikoprotein limfocitov (CD52).
Nervous system disorders: Intracranial haemorrhage has occurred with fatal outcome, in patients with 
Bolezni živčevja: pri bolnikih s trombocitopenijo je prišlo do intrakranialnih krvavitev s smrtnim izidom.
These effects will gradually reduce as treatment is continued. 
Med nadaljevanjem zdravljenja se bodo neželeni učinki postopoma zmanjšali.
Approximately 97% of first-line patients experienced adverse reactions; the most commonly reported reactions in first line patients usually occurred in the first week of therapy. 
Neželeni učinki so se pojavili pri približno 97 odstotkih predhodno nezdravljenih bolnikov (zdravljenje prvega izbora); najpogosteje so se neželeni učinki pojavili v prvem tednu zdravljenja.
Very common 
Pogosto
MabCampath is administered into one of your veins via a drip (see also ‘information intended for 
Infundiranje zdravila MabCampath poteka preko infuzijske cevke v eno od vaših ven (glejte tudi informacije namenjene zdravstvenemu osebju).
Very common side effects (seen in at least 1 in every 10 patients treated in clinical trials): 
Zelo pogosti neželeni učinki (opazili so jih pri najmanj 1 od 10 bolnikov v kliničnih preskušanjih)
MabCampath should be permanently discontinued if autoimmune anaemia or autoimmune thrombocytopenia appears. 
Uporabo zdravila MabCampath je treba trajno prenehati, če pride do pojava avtoimunske anemije ali avtoimunske trombocitopenije.
The most frequent serious adverse reactions are cytopenias, infusion reactions, and 
Najpogostejši resni neželeni učinki so citopenije, reakcije zaradi infundiranja in imunosupresija/okužbe.
• high blood pressure, fast or slow heart rate, feeling your heart racing, blood vessel spasm • becoming red in the face, bruising of the skin 
• visok krvni tlak, hiter ali počasen srčni utrip, občutek razbijanja srca, žilni spazem
Ongoing clinical assessment should be performed for symptomatic CMV infection during MabCampath treatment and for at least 2 months 
Bolnike s simptomatskimi okužbami s CMV je treba med zdravljenjem z zdravilom MabCampath in še vsaj dva meseca po končanem zdravljenju redno klinično spremljati.
Severe anaphylactic and other hypersensitivity reactions 
Bolezni imunskega sistema alergijske reakcije hude anafilaktične in druge preobčutljivostne reakcije